Greater plaque burden and cholesterol content may explain an increased incidence of non-culprit events in diabetic patients: a Lipid-Rich Plaque substudy.


Journal

European heart journal. Cardiovascular Imaging
ISSN: 2047-2412
Titre abrégé: Eur Heart J Cardiovasc Imaging
Pays: England
ID NLM: 101573788

Informations de publication

Date de publication:
21 07 2022
Historique:
received: 12 04 2021
accepted: 22 09 2021
pubmed: 28 9 2021
medline: 26 7 2022
entrez: 27 9 2021
Statut: ppublish

Résumé

Diabetes mellitus (DM) is associated with increased cardiovascular morbidity and mortality. The multicentre, prospective Lipid-Rich Plaque trial (LRP) examined non-culprit (NC) non-obstructive coronary segments with a combined near-infrared spectroscopy (NIRS)-intravascular ultrasound (IVUS) catheter. This study assessed the differences in NC plaque characteristics and their influence on major adverse cardiac events (MACE) in diabetic and non-diabetic patients. Patients with known DM status were divided into no diabetes, diabetes not treated with insulin (non-ITDM), and insulin-treated diabetes (ITDM). The association between presence and type of DM and NC-MACE was assessed at both the patient and coronary segment levels by Cox proportional regression modelling. Out of 1552 patients enrolled, 1266 who had their diabetes status recorded were followed through 24 months. Female sex, hypertension, chronic kidney disease, peripheral vascular disease, and high body mass index were significantly more frequent in diabetic patients. The ITDM group had more diseased vessels, at least one NC segment with a maxLCBI4 mm ≥400 in 46.2% of patients, and maxLCBI4 mm ≥400 in nearly one out of six Ware segments (15.2%, 125/824 segments). The average maxLCBI4 mm significantly increased from non-diabetic patients (NoDM) to non-insulin-treated diabetic patients (non-ITDM) to insulin-treated diabetic patients (ITDM; 137.7 ± 161.9, 154.8 ± 173.6, 182.9 ± 193.2, P < 0.001, respectively). In patients assigned to follow-up (692 ± 129 days), ITDM doubled the incidence of NC-MACE compared with the absence of diabetes (15.7% vs. 6.9%, P = 0.0008). The presence of maxLCBI4 mm>400 further increased the NC-MACE rate to 21.6% (Kaplan-Meier estimate). Cholesterol-rich NC plaques detected by NIRS-IVUS were significantly more frequent in diabetic patients, especially those who were insulin-treated, and were associated with an increased NC-MACE during follow-up.

Identifiants

pubmed: 34568945
pii: 6375567
doi: 10.1093/ehjci/jeab161
doi:

Substances chimiques

Insulin 0
Lipids 0
Cholesterol 97C5T2UQ7J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1098-1107

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Auteurs

Pierluigi Demola (P)

Department of Clinical and Experimental Medicine, Structural Interventional Cardiology, Careggi University Hospital, Largo Brambilla 3, 50139 Florence, Italy.

Carlo Di Mario (C)

Department of Clinical and Experimental Medicine, Structural Interventional Cardiology, Careggi University Hospital, Largo Brambilla 3, 50139 Florence, Italy.

Rebecca Torguson (R)

The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Tim Ten Cate (T)

Cardiology Department, Radboud University Medical Center, Nijmegen, The Netherlands.

Gabriele Bambagioni (G)

Department of Clinical and Experimental Medicine, Structural Interventional Cardiology, Careggi University Hospital, Largo Brambilla 3, 50139 Florence, Italy.

Ziad Ali (Z)

St. Francis Hospital-The Heart Center, Roslyn, NY, USA.

William Skinner (W)

Cardiovascular Department, Central Baptist Hospital, Lexington, KY, USA.

Andre Artis (A)

Cardiovascular Department, Methodist Hospital, Merrillville, IN, USA.

Cheng Zhang (C)

Cardiovascular Department, MedStar Washington Hospital Center, Washington, DC, USA.

Hector M Garcia-Garcia (HM)

Cardiovascular Department, MedStar Washington Hospital Center, Washington, DC, USA.

Gheorghe Doros (G)

Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.

Gary S Mintz (GS)

Cardiovascular Department, MedStar Washington Hospital Center, Washington, DC, USA.

Ron Waksman (R)

Cardiovascular Department, MedStar Washington Hospital Center, Washington, DC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH